Polymorphisms in genes involved in the mechanism of action of methotrexate: Are they associated with outcome in rheumatoid arthritis patients?

Pharmacogenomics

Volumn 15, Issue 8, 2014, Pages 1079-1090

  Salazar, Juliana ^a,b   Moya, Patricia ^a,c   Altés, Albert ^d   Díaz Torné, César ^a   Casademont, Jordi ^a   Cerdà Gabaroi, Dacia ^e   Corominas, Hèctor ^e   Baiget, Montserrat ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Althaia   (Spain)

^e Moises Broggi Hospital Sant Joan d'Espì   (Spain)

Author keywords

5,10 methylenetetrahydrofolate reductase; 5 aminoimidazole 4 carboxamide ribonucleotide transformylase; ATIC; DHFR; dihydrofolate reductase; methotrexate; MTHFR; rheumatoid arthritis

Indexed keywords

METHOTREXATE; CCND1 PROTEIN, HUMAN; CYCLIN D1; DEAMINASE; DIHYDROFOLATE REDUCTASE; INOSINE MONOPHOSPHATE SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; MULTIENZYME COMPLEX; PHARMACOLOGICAL BIOMARKER; TRANSFERASE;

ADULT; ALOPECIA; ARTICLE; ATIC GENE; CCND1 GENE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DHFR GENE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH ULCER; MTHFR GENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TYMS GENE; URINARY TRACT INFECTION; ADVERSE DRUG REACTION; ARTHRITIS, RHEUMATOID; CLASSIFICATION; GENETICS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; CYCLIN D1; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIENZYME COMPLEXES; NUCLEOTIDE DEAMINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT OUTCOME;

EID: 84905510247     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.67     Document Type: Article

References (30)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205-2219 (2011).
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73(3), 492-509 (2014).
3. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCIT). Ann. Rheum. Dis. 66(1), 34-45 (2007).
4. Saag KG, Teng GG, Patkar N et al. American College of Rheumatology 2008 recommendations for the use of non biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arhritis Rheum. 59(6), 762-784 (2008).
5. Yazici Y. Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 28(Suppl. 61), S65-S67 (2010).
6. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 37(10), 1492-1498 (1994).
7. Kinder AJ, Hassell AB, Brand J et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 44(1), 61-66 (2005).
8. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41(12), 1367-1374 (2002).
9. Maetzel A, Wong A, Strand V et al. Meta-analyses of treatment termination rates among rheumatoid arthritis patients receiving disease modifying anti-rheumatic drugs. Rheumatology (Oxford) 39(9), 975-981 (2000).
10. Albrecht K, Müller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin. Exp. Rheumatol. 28(Suppl. 61), S95-S101 (2010).
11. Mikkelsen TS, Thorn CF, Yang JJ et al. PharmGKB summary: methotrexate pathway. Pharmacogenet. Genomics 21(10), 679-686 (2011).
12. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol. Pharmacol. 17(1), 105-110 (1980).
13. Gorlick R, Goker E, Trippett T et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335(14), 1041-1048 (1996).
14. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92(6), 2675-2682 (1993).
15. Prevoo ML, vant Hof MA, Kuper HH et al. Modified disease-activity scores that include 28-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44-48 (1995).
16. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23(5 Suppl. 39), S100-S108 (2005).
17. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin. Exp. Rheumatol. 23(Suppl. 39), S93-S99 (2005).
18. Dulucq S, St-Onge G, Gagné V et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 111(7), 3692-3700 (2008).
19. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell. Struct. Funct. 20(3), 191-197 (1995).
20. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63(18), 6004-6007 (2003).
21. Regulome database. http://regulome.stanford.edu
22. Boyle AP, Hong EL, Hariharan M et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22(9), 1790-1797 (2012).
23. Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin. Drug. Investig. 30(2), 101-108 (2010).
24. Owen SA, Lunt M, Bowes J, Hider SL et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. 13(2), 137-147 (2013).
25. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006).
26. Milic V, Jekic B, Lukovic L et al. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 30(2), 178-183 (2012).
27. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment. Pharmacogenomics J. 13(3), 227-234 (2013).
28. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007).
29. Fransen J, Kooloos WM, Wessels JA, Huizinga TW, Guchelaar HJ, van Riel PL, Barrera P. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 13(9), 1087-1094 (2012).
30. Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 14(3), 305-314 (2013).